Cyprotex (CRX)
market vs.
industry GROWTH & VALUE
| 12m Forecast Rolling | ||||
| PE Ratio (f) | 9.55 |
|
|
|
| PEG Ratio (f) |
|
|
||
| EPS Growth (f) | % |
|
|
|
| Dividend Yield (f) | % |
|
|
|
| Valuation (ttm) | ||||
| Price to Book Value | 1.21 |
|
|
|
| Price to Tang. Book |
|
|
||
| Price to Free Cashflow |
|
|
||
| Price to Sales |
|
|
||
| EV to EBITDA |
|
|
||
market vs.
industry QUALITY
| Year End 31st Dec | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013E | 2014E | CAGR / Avg | |
| Revenue | £m | |||||||||
| Operating Profit | £m | |||||||||
| Net Profit | £m | |||||||||
| EPS Reported | p | |||||||||
| EPS Normalised | p | |||||||||
| EPS Growth | % | |||||||||
| PE Ratio | x | |||||||||
| PEG | x | |||||||||
| Profitability | ||||||||||
| Operating Margin | % | |||||||||
| ROA | % | |||||||||
| ROCE | % | |||||||||
| ROE | % | |||||||||
| Cashflow | ||||||||||
| Op. Cashflow ps | p | |||||||||
| Capex ps | p | |||||||||
| Free Cashflow ps | p | |||||||||
| Dividends | ||||||||||
| Dividend ps | p | |||||||||
| Dividend Growth | % | |||||||||
| Dividend Yield | % | |||||||||
| Dividend Cover | x | |||||||||
| Balance Sheet | ||||||||||
| Cash etc | £m | |||||||||
| Working Capital | £m | |||||||||
| Net Fixed Assets | £m | |||||||||
| Net Debt | £m | |||||||||
| Book Value | £m | |||||||||
| Average Shares | m | |||||||||
| Book Value ps | p | +29.1% | ||||||||
FINANCIAL BRIEF: For the fiscal year ended 31 December 2012, Cyprotex plc revenues increased 5% to L8.3M. Net income decreased 77% to L203K. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net income was offset by Administrative costs increase of 10% to L6.5M (expense). more »
| Leverage (ttm) | Total | Ex Intang | |||
| Gross Gearing | % | ||||
| Net Gearing | % | ||||
| Cash / Assets | % | ||||
| Liquidity (ttm) | ||
| Current Ratio | ||
| Quick Ratio | ||
| Interest Cover | ||
| Efficiency (ttm) | ||
| Asset Turnover | ||
| Rec's Turnover | ||
| Stock Turnover | ||
market vs.
industry RECENT HISTORY
| Latest interim period (ended 31st Dec '12) vs. prior year | ||||
| Sales Growth | % |
|
|
|
| EPS Growth | % |
|
|
|
| 3yr Average Annualised | ||||
| Sales Growth | % |
|
|
|
| EPS Growth | % |
|
|
|
| DPS Growth | % |
|
|
|
BROKER CONSENSUS & FORECAST TREND
| Recommendation: | Strong Sell | Sell | Hold | Buy | Strong Buy |
|---|---|---|---|---|---|
| No. of Analysts: |
Cyprotex PLC (Cyprotex) is a holding company specializing in preclinical ADME Tox, both in vitro (laboratory experiments) and in silico (computer modelling). The principal activities of the Company, along with its subsidiaries, are that of providing in vitro and in silico Absorption, Distribution, Metabolism, Excretion, Toxicity and Pharmacokinetics (ADMET and PK) information to the pharmaceutical and biotechnology industries. The Company’s in vitro ADME and DMPK services include in vitro metabolism, in vitro permeability and transporters, solubility and physicochemical properties, in vitro protein binding and PK and bioanalysis. Cyprotex serves drug-discovery organizations, which include pharmaceutical companies, small virtual companies, as well as academic and not-for-profit laboratories. It also supports the research efforts of the cosmetic and agrochemical industries, principally for in vitro toxicity testing. Its subsidiaries are Cyprotex Discovery Limited and Apredica, LLC.
Directors: Anthony Baxter (CEO) 53, John Dootson (CFO) 50, Mark Warburton (Secy.) ,
No. of Employees: 71 No. of Shareholders: n/a
| Last Annual | December 31st, 2012 |
| Last Interim | December 31st, 2012 |
| Shares in Issue | 223,687,485 |
| Free Float | 57.4m (25.7%) |
| Sector | Healthcare |
| Industry | Biotechnology & Medical Research |
| Index | FTSE Aim All Share, |
| Exchange |
London Stock Exchange (AIM) |
| Eligible for | an ISA? a SIPP? |
| Address | , MACCLESFIELD, SK10 2DR, United Kingdom |
| Web | http://www.cyprotex.com/ |
| Phone | +44 1625 505100 |
| Contact | Anthony Baxter (Chief Executive Officer, Executive Director) |
| Registrar | Capita Registrars Limited (Huddersfield) |
| Auditors | Ernst & Young LLP |
| 4th Jun | Issue of Equity |
| 21st May | Holding(s) in Company |
| 21st May | Holding(s) in Company |
| 1st May | Contract with U.S. EPA |
| 21st Mar | Final Results |
| 15th Mar | Notice of Results |
Recent ↓
